To date, BRAF mutations account for about 7% of all human solid tumors, with a high prevalence in papillary thyroid carcinomas (PTC), melanomas, colorectal cancers (CRC), and lung cancers [20,22,23,24,25,26,27]. This evidence concerns the gene BRAF and lung carcinoma.